Search results for "Imaging"

showing 10 items of 6802 documents

Toll like receptor mediated immune stimulation can be visualized in vivo by [ 18 F]FDG-PET

2016

Abstract Introduction High uptake of [ 18 F]-2-fluorodeoxyglucose ([ 18 F]FDG) by inflammatory cells is a frequent cause of false positive results in [ 18 F]FDG-positron-emission tomography (PET) for cancer diagnostics. Similar to cancer cells, immune cells undergo significant increases in glucose utilization following activation, e.g., in infectious diseases or after vaccination during cancer therapy. The aim of this study was to quantify certain immune effects in vitro and in vivo by [ 18 F]FDG-PET after stimulation with TLR ligands and specific antibodies. Methods In vivo [ 18 F]FDG-PET/magnetic resonance imaging (MRI) and biodistribution was performed with C57BL/6 mice immunized with Cp…

0301 basic medicineCD86Cancer ResearchPathologymedicine.medical_specialtyB-cell receptorCD28Biology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmune systemIn vivo030220 oncology & carcinogenesisCancer cellmedicineCancer researchMolecular MedicineRadiology Nuclear Medicine and imagingLymph nodeCD80Nuclear Medicine and Biology
researchProduct

The Barrett‐associated variants at GDF 7 and TBX 5 also increase esophageal adenocarcinoma risk

2016

Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) represent two stages within the esophagitis-metaplasia-dysplasia-adenocarcinoma sequence. Previously genetic risk factors have been identified that confer risk to BE and EAC development. However, to which extent the genetic variants confer risk to different stages of the BE/EAC sequence remains mainly unknown. In this study we analyzed three most recently identified BE variants at the genes GDF7 (rs3072), TBX5 (rs2701108), and ALDH1A2 (rs3784262) separately in BE and EAC samples in order to determine their risk effects during BE/EAC sequence. Our data show that rs3072 at GDF7 and rs2701108 at TBX5 are also associated with EAC and …

0301 basic medicineCancer ResearchCase-control studyGenome-wide association studyLocus (genetics)Biologymedicine.diseaseBioinformaticshumanitiesALDH1A203 medical and health sciences030104 developmental biologymedicine.anatomical_structureOncologyGenetic variationCancer researchmedicineAdenocarcinomaRadiology Nuclear Medicine and imagingEsophagusGeneCancer Medicine
researchProduct

Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Compariso…

2021

The objective of this study is to conduct a qualitative and a quantitative image quality and lesion evaluation in patients undergoing MR-guided radiation therapy (MRgRT) for prostate cancer on a hybrid magnetic resonance imaging and linear accelerator system (MR-Linac or MRL) at 1.5 Tesla. This prospective study was approved by the institutional review board. A total of 13 consecutive patients with biopsy-confirmed prostate cancer and an indication for MRgRT were included. Prior to radiation therapy, each patient underwent an MR-examination on an MRL and on a standard MRI scanner at 3 Tesla (MRI3T). Three readers (two radiologists and a radiation oncologist) conducted an independent qualita…

0301 basic medicineCancer ResearchIntraclass correlationImage qualityPIRADSFleiss' kappalcsh:RC254-282ArticleLesion03 medical and health sciences0302 clinical medicineimage qualityMedicineEffective diffusion coefficientimage guidanceRadiation oncologistMR-Linacmedicine.diagnostic_testbusiness.industryMagnetic resonance imaginglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslesion detection030104 developmental biologyadaptive radiotherapyOncologyprostate carcinoma030220 oncology & carcinogenesismpMRImedicine.symptombusinessNuclear medicineKappaCancers
researchProduct

Potential of induced metabolic bioluminescence imaging to uncover metabolic effects of antiangiogenic therapy in tumors

2016

Tumor heterogeneity at the genetic level has been illustrated by a multitude of studies on the genomics of cancer, but whether tumors can be heterogeneous at the metabolic level is an issue which has been less systematically investigated so far. A burning related question is whether the metabolic features of tumors can change either following natural tumor progression (i.e. in primary tumors versus metastasis) or therapeutic interventions. In this regard, recent findings by independent teams indicate that anti-angiogenic drugs cause metabolic perturbations in tumors as well as metabolic adaptations associated with increased malignancy. Induced metabolic bioluminescence imaging (imBI) is an …

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyAngiogenesisMini ReviewBiologyMalignancylcsh:RC254-282MetastasisImaging03 medical and health sciencesAngiogenesis; Cancer mouse models; Glycolysis; Imaging; MetabolismmedicineBioluminescence imagingGlycolysismouse modelsCancerCancerMetabolismlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyMetabolismOncologyTumor progressionCancer researchAngiogenesisGlycolysis
researchProduct

Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique

2016

Abstract Patients with malignant gliomas have a poor prognosis with average survival of less than one year. Whereas in other tumor entities the characteristics of tumor metabolism are successfully used for therapeutic approaches, such developments are very rare in brain tumors, notably in gliomas. One metabolic feature characteristic of gliomas, in particular diffuse astrocytomas and oligodendroglial tumors, is the variable content of D-2-hydroxyglutarate (D2HG), a metabolite, which was discovered first in this tumor entity. D2HG is generated in large amounts due to various “gain-of–function” mutations in the isocitrate dehydrogenases IDH-1 and IDH-2. Meanwhile, D2HG has been detected in se…

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyMetabolite610 MedizinBiology03 medical and health scienceschemistry.chemical_compoundmedicineBioluminescence imagingBioluminescenceOligodendroglial TumorOriginal Researchddc:610D-2 hydroxyglutarateglioblastomaMyeloid leukemiaCancerACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; IDH2 MUTATIONS; CHROMATOGRAPHY/MASS SPECTROMETRY; MAGNETIC-RESONANCE; 2-HYDROXYGLUTARATE; CANCER; GLIOMAS; L-2-HYDROXYGLUTARATE; METABOLITES; D-2 hydroxyglutarate; IDH mutations; bioluminescence imaging; oncometabolite; glioblastomabioluminescence imagingIDH mutationsmedicine.diseaseoncometaboliteLymphoma030104 developmental biologychemistryOncologyChondrosarcoma
researchProduct

Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases.

2021

Thymic hyperplasia (TH) with lymphoepithelial sialadenitis (LESA)-like features (LESA-like TH) has been described as a tumor-like, benign proliferation of thymic epithelial cells and lymphoid follicles. We aimed to determine the frequency of lymphoma and autoimmunity in LESA-like TH and performed retrospective analysis of cases with LESA-like TH and/or thymic MALT-lymphoma. Among 36 patients (21 males) with LESA-like TH (age 52 years, 32&ndash

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyPure red cell aplasia610 Medicine & healthautoimmune diseaselymphomathymitismedicine.disease_causelcsh:RC254-282SclerodermaArticleAutoimmunitysurgery03 medical and health sciences0302 clinical medicinethymusimmune system diseaseshemic and lymphatic diseasesmedicineddc:610Autoimmune diseasebusiness.industryLESAimagingHyperplasialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseLESA; autoimmune disease; imaging; lymphoma; myasthenia; pathology; surgery; thymic epithelial tumor; thymitis; thymusSialadenitisMyasthenia gravis3. Good healthLymphomamyasthenia030104 developmental biologyOncologythymic epithelial tumor030220 oncology & carcinogenesis570 Life sciences; biologypathologybusiness
researchProduct

2021

Background Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. Methods This study highlights the relevance of a distinct immune signature in the blood for response to ICI therapy and overall survival (OS). Therefore, the immune cell composition in the peripheral blood of 45 melanoma patients prior to ICI therapy was analyzed by flow cytometry and complete blood count. Results Responders to ICI therapy displayed an abundance of proliferating CD4+ T cells, an increased lymphocyte-to-monocyte…

0301 basic medicineCancer ResearchPredictive markermedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentMelanomaComplete blood countImmunotherapymedicine.diseaseFlow cytometry03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesismedicineMyeloid-derived Suppressor CellCancer researchRadiology Nuclear Medicine and imagingSkin cancerbusinessCancer Medicine
researchProduct

Exosomes in semen: opportunities as a new tool in prostate cancer diagnosis

2017

Abstract: Prostate cancer (PCa) is the most common cancer in men. Nowadays, it is diagnosed through the test of serum prostate-specific antigen (PSA) and rectal examination; however, there is still debate about the PSA-based diagnosis. Seminal fluid (SF), contains a high concentration of subcellular lipid-bound microparticles, traditionally termed "prostasomes", that are extracellular vesicles (EVs) released into the extracellular space by prostate gland's epithelial cells. These vesicles, first described in 1982 promote motility of sperm cells, regulation of sperm cell capacitation, acrosome reaction and immune suppression within the female reproductive tract. It was demonstrated that pros…

0301 basic medicineCancer ResearchSexual transmissionAcrosome reactionSemenimmunomodulationurologic and male genital diseasesMetastasisAndrology03 medical and health sciencesProstate cancermedicineexosomeRadiology Nuclear Medicine and imagingProstate cancer (PCa)Prostate cancer (PCa); exosomes; seminal liquid; immunomodulationbusiness.industrymedicine.diseaseSpermMicrovesicles030104 developmental biologyOncologyProstasomesHuman medicineseminal liquidbusinessTranslational Cancer Research
researchProduct

Impact des facteurs nutritionnels pendant et après cancer

2021

Nutritional factors (diet, weight, alcohol, physical activity) are identified as factors having an impact on the onset of several cancer sites. Less abundant scientific data also underline their impact on the tumor progression. A review of the scientific literature was carried out by a group of experts established by the French National Cancer Institute (INCa) to better document the influence of nutritional factors during and after cancer on outcomes such as overall mortality, cancer specific mortality, recurrence, second primary cancers and quality of life. This analysis of the literature completes messages of reduction of alcohol consumption, prevention of undernutrition or excess weight …

0301 basic medicineCancer Researchbusiness.industryCancerHematologyGeneral MedicineScientific literaturemedicine.disease03 medical and health sciencesMalnutrition030104 developmental biology0302 clinical medicineQuality of life (healthcare)OncologyTumor progression030220 oncology & carcinogenesisEnvironmental healthmedicineRadiology Nuclear Medicine and imagingbusinessCancer specific mortalitySedentary lifestyleTertiary PreventionBulletin du Cancer
researchProduct

Attachement et parcours de l’aidant face à l’épreuve du cancer

2020

Resume Introduction Depuis le dernier plan cancer 2014–2019, l’evaluation des repercussions de la maladie chez les aidants est devenue essentielle. En effet, la qualite de la relation d’aide participe a la qualite de vie du malade. Dans ce contexte, l’objectif principal de cette etude etait de decrire l’evolution de l’attachement de l’aidant de patients ayant un cancer pendant les trois premieres annees d’accompagnement de la maladie. Methode Les aidants ont ete recrutes dans le cadre de l’etude ICE (Informal Carers of Elderly) et accompagnaient un proche, âge de plus de 60 ans, atteint d’un cancer colorectal, du sein ou de la prostate. Ils ont ete rencontres a domicile dans les trois mois …

0301 basic medicineCancer Researchmedia_common.quotation_subjectHematologyGeneral MedicineArt03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisRadiology Nuclear Medicine and imagingHumanitiesmedia_commonBulletin du Cancer
researchProduct